RxDoctor Payments DataLook up a doctor →

Verena Samara, MD

Neurology · Reno, NVNPI 1376886846

Payments from drug & device makers

$64,007in general payments, 2019–2025

Across 420 payments — averaging $152.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$32K
  • Argenx US, Inc.$16K
  • Johnson & Johnson$8K
  • AstraZeneca$3K
  • AbbVie$1K
  • Pfizer$755
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$7,33611%
  • Speaking & faculty fees$44,58870%
  • Travel & lodging$3,2745%
  • Food & beverage$8,79614%
  • Education$130%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,007 in reported general payments places this provider in the 80th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$148,633
Medicare patients
288
Services billed
5,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina31$38,604
RytaryCarbidopa/Levodopa13$13,863
Carbidopa-LevodopaCarbidopa/Levodopa75$3,303
Mycophenolate Mofetil14$2,727
Primidone23$1,713
Gabapentin47$1,353
Duloxetine Hcl44$1,201
Pyridostigmine Bromide15$1,024
Propranolol Hcl19$739
Pregabalin31$621
Baclofen16$341
Nortriptyline Hcl23$277
Pramipexole DihydrochloridePramipexole Di-Hcl13$221
Topiramate12$164
Amitriptyline Hcl12$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$1,148$38,60431 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$128$17,61442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 neurology providers in Nevada.

Other neurology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →